FMA
TVTX icon

FNY Managed Accounts’s Travere Therapeutics TVTX Stock Holding History

FNY Managed Accounts’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-500
Closed -$11.2K – 264
2016
Q3 		$11.2K Buy
+500
New +$9.52K 0.01% 312

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FNY Managed Accounts's TVTX Position: Q4 2016 in Review

FNY Managed Accounts sold out of Travere Therapeutics (TVTX) in Q4 2016, closing a stake of 500 shares — an estimated $11.2K sold.

FNY Managed Accounts first reported a position in TVTX in Q3 2016 and held it in 1 quarter. The position peaked at $11.2K in Q3 2016. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

  • FNY Managed Accounts reported no remaining Travere Therapeutics position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 500 Travere Therapeutics shares in Q4 2016, an estimated $11.2K.
  • FNY Managed Accounts first reported a position in Travere Therapeutics in Q3 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Travere Therapeutics position peaked at $11.2K in Q3 2016.
  • 121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.